Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
22 February 2017 - 8:01AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a
biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat grievous
blood-based disorders with significant unmet need, today announced
an agreement to sell $75.00 million in shares of its common stock
in a registered underwritten public offering. In addition, GBT has
granted the underwriter a 30-day option to purchase up to $11.25
million in shares of its common stock.
Cantor Fitzgerald & Co. is the sole book-running manager for
the offering.
GBT intends to use the net proceeds from the offering for
development relating to its lead product candidate GBT440, other
research and development activities and for working capital and
general corporate purposes.
A shelf registration statement relating to the shares of common
stock offered in the public offering described above was filed with
the Securities and Exchange Commission (SEC) on October 14, 2016
and declared effective by the SEC on October 28, 2016. The
securities may be offered only by means of a written prospectus,
including a prospectus supplement, forming a part of the effective
registration statement. A preliminary prospectus supplement and
accompanying prospectus relating to the offering will be filed with
the SEC and will be available on the SEC’s website at www.sec.gov.
When available, copies of the preliminary prospectus supplement and
the accompanying prospectus may also be obtained by contacting
Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park
Ave., 6th Floor, New York, New York 10022, or by telephone at
212-829-7122, or by email at prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Global Blood TherapeuticsGlobal Blood
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
dedicated to discovering, developing and commercializing novel
therapeutics to treat grievous blood-based disorders with
significant unmet need. GBT is developing its lead product
candidate, GBT440, as an oral, once-daily therapy for sickle cell
disease. GBT is also investigating GBT440 for the treatment of
hypoxemic pulmonary disorders including idiopathic pulmonary
fibrosis.
Forward-Looking Statements Certain statements
in this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements about GBT’s anticipated public offering, anticipated use
of proceeds and other statements containing the words “anticipate,”
“planned,” “believe,” “forecast,” “estimated,” “expected,” and
“intend,” among others. These forward-looking statements are based
on GBT’s current expectations and actual results could differ
materially. Statements we make in this press release may include
statements that are not historical facts and are considered
forward-looking within the meaning of Section 27A of the Securities
Act of 1933, as amended and Section 21E of the Securities Exchange
Act of 1934, as amended. We intend these forward-looking
statements, including statements regarding the therapeutic
potential and safety profile of GBT440, and our ability to
implement our clinical development plans for GBT440, to be covered
by the safe harbor provisions for forward-looking statements
contained in Section 27A of the Securities Act and Section 21E of
the Securities Exchange Act and are making this statement for
purposes of complying with those safe harbor provisions. These
forward-looking statements reflect our current views about our
plans, intentions, expectations, strategies and prospects, which
are based on the information currently available to us and on
assumptions we have made. We give no assurance that the plans,
intentions, expectations or strategies will be attained or
achieved, and furthermore, actual results may differ materially
from those described in the forward-looking statements and will be
affected by a variety of risks and factors that are beyond our
control including, without limitation, the risks that our clinical
and preclinical development activities may be delayed or terminated
for a variety of reasons, that regulatory authorities may disagree
with our clinical development plans or require additional studies
or data to support further clinical investigation of our product
candidates, and that drug-related adverse events may be observed in
later stages of clinical development, along with those risks set
forth in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2015, and in our Quarterly Reports on Form 10-Q for
the quarters ended March 31, 2016, June 30, 2016 and September 30,
2016, as well as discussions of potential risks, uncertainties and
other important factors in our subsequent filings with the U.S.
Securities and Exchange Commission. Except as required by law, we
assume no obligation to update publicly any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
investor@globalbloodtx.com
Julie Normart (media)
Pure Communications
415-946-1087
media@globalbloodtx.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2024 to May 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From May 2023 to May 2024